PTC Therapeutics (PTCT) Competitors $39.23 -3.15 (-7.43%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PTCT vs. CCXI, FTSV, ZGNX, TGTX, IONS, RDY, PCVX, SRPT, CTLT, and RVMDShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include ChemoCentryx (CCXI), Forty Seven (FTSV), Zogenix (ZGNX), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector. PTC Therapeutics vs. ChemoCentryx Forty Seven Zogenix TG Therapeutics Ionis Pharmaceuticals Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Catalent Revolution Medicines ChemoCentryx (NASDAQ:CCXI) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation. Does the MarketBeat Community believe in CCXI or PTCT? PTC Therapeutics received 211 more outperform votes than ChemoCentryx when rated by MarketBeat users. Likewise, 61.86% of users gave PTC Therapeutics an outperform vote while only 57.48% of users gave ChemoCentryx an outperform vote. CompanyUnderperformOutperformChemoCentryxOutperform Votes34257.48% Underperform Votes25342.52% PTC TherapeuticsOutperform Votes55361.86% Underperform Votes34138.14% Is CCXI or PTCT more profitable? PTC Therapeutics has a net margin of -50.32% compared to ChemoCentryx's net margin of -357.01%. PTC Therapeutics' return on equity of 0.00% beat ChemoCentryx's return on equity.Company Net Margins Return on Equity Return on Assets ChemoCentryx-357.01% -48.52% -30.59% PTC Therapeutics -50.32%N/A -16.44% Which has more risk and volatility, CCXI or PTCT? ChemoCentryx has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Do analysts recommend CCXI or PTCT? PTC Therapeutics has a consensus price target of $41.31, indicating a potential upside of 5.30%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than ChemoCentryx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ChemoCentryx 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PTC Therapeutics 3 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.33 Does the media prefer CCXI or PTCT? In the previous week, PTC Therapeutics had 11 more articles in the media than ChemoCentryx. MarketBeat recorded 11 mentions for PTC Therapeutics and 0 mentions for ChemoCentryx. PTC Therapeutics' average media sentiment score of 0.57 beat ChemoCentryx's score of 0.19 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ChemoCentryx Neutral PTC Therapeutics Positive Do institutionals & insiders have more ownership in CCXI or PTCT? 81.1% of ChemoCentryx shares are owned by institutional investors. 8.3% of ChemoCentryx shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, CCXI or PTCT? ChemoCentryx has higher earnings, but lower revenue than PTC Therapeutics. ChemoCentryx is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemoCentryx$32.22M115.14-$131.76M-$1.89-27.51PTC Therapeutics$937.82M3.23-$626.60M-$5.94-6.60 SummaryPTC Therapeutics beats ChemoCentryx on 13 of the 19 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.03B$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-6.6010.92101.9217.46Price / Sales3.23245.131,196.9569.07Price / Cash18.1753.4941.0436.36Price / Book-2.879.306.345.87Net Income-$626.60M$154.14M$119.64M$225.66M7 Day Performance-11.40%-9.47%-5.13%-1.34%1 Month Performance6.00%-7.30%-2.72%1.15%1 Year Performance91.74%28.21%31.10%24.02% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics2.7835 of 5 stars$39.23-7.4%$41.31+5.3%+96.2%$3.03B$937.82M-6.601,410News CoverageCCXIChemoCentryx0.7532 of 5 stars$51.99flatN/A+0.0%$3.71B$32.22M-27.51178Analyst ForecastFTSVForty SevenN/A$95.51flatN/AN/A$4.60B$15.68M-38.6757ZGNXZogenixN/A$26.68flatN/A+0.0%$1.50B$81.69M-6.56218Analyst ForecastTGTXTG Therapeutics4.6026 of 5 stars$30.85-11.6%N/A+162.3%$5.43B$233.66M-308.42290Insider SellingHigh Trading VolumeIONSIonis Pharmaceuticals4.0875 of 5 stars$37.23-1.5%N/A-29.3%$5.97B$788M-15.26800Analyst DowngradeInsider SellingShort Interest ↑News CoverageRDYDr. Reddy's Laboratories1.3454 of 5 stars$14.24-2.2%N/A+6.7%$12.15B$3.35B22.7527,048Analyst DowngradeShort Interest ↑PCVXVaxcyte3.3295 of 5 stars$92.68-4.1%N/A+73.3%$12.04BN/A-20.15160News CoverageHigh Trading VolumeSRPTSarepta Therapeutics4.9455 of 5 stars$109.11-3.0%N/A+26.0%$10.74B$1.24B87.291,314Analyst UpgradeCTLTCatalent2.8783 of 5 stars$58.95-0.3%N/A+48.7%$10.74B$4.38B-26.0816,900Analyst UpgradeInsider SellingNews CoverageRVMDRevolution Medicines3.5596 of 5 stars$57.37-1.3%N/A+159.4%$9.78B$11.58M-15.98443 Related Companies and Tools Related Companies CCXI Alternatives FTSV Alternatives ZGNX Alternatives TGTX Alternatives IONS Alternatives RDY Alternatives PCVX Alternatives SRPT Alternatives CTLT Alternatives RVMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTCT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts